USPTO serial 79378223
SOLICI
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 20, 2024
- Examiner
- HARMON, RAYMOND E
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SOLICI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Cambridge Healthcare Research Limited
GB
Other trademarks owned by Cambridge Healthcare Research Limited
Cambridge Healthcare Research Limited
GB
Other trademarks owned by Cambridge Healthcare Research Limited
Cambridge Healthcare Research Limited
GB
Other trademarks owned by Cambridge Healthcare Research Limited
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
PETER J RIEBLING
PETER J RIEBLING Riebling IP, PLLC1717 Pennsylvania Ave NW, Suite 1025Washington, DC 20006United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 035 | Providing business advice, information and consultancy for the pharmaceutical, biopharmaceutical and medical device industries; providing business information about pharmaceutical, biopharmaceutical and medical device products and companies; market research for the pharmaceutical, biopharmaceutical and medical device industries; business research and market analysis for the pharmaceutical, biopharmaceutical and medical device industries; business consultancy, namely, strategic consulting and assistance with business decisions in the pharmaceutical, biopharmaceutical and medical device industries; business consultancy, namely, competitor landscaping, competitor monitoring, business competitive intelligence for the pharmaceutical biopharmaceutical and medical device industries; preparing reports on all the aforesaid | ACTIVE | — |
| 042 | Providing scientific and technological information, advice and consultancy for the pharmaceutical, biopharmaceutical and medical device industries; scientific research consulting, namely, scientific research and analysis for the pharmaceutical, biopharmaceutical and medical device industries; scientific research consulting, namely, scientific and technological landscaping for the pharmaceutical, biopharmaceutical and medical device industries; quality control for others, namely, assessment and benchmarking of pharmaceutical, biopharmaceutical and medical device products; quality control for others, namely, researching, analysing and assessment of pharmaceutical, biopharmaceutical and medical device products for others; providing scientific information about pharmaceutical, biopharmaceutical and medical device products and companies; scientific research consulting, namely, preparing advice and reports on all the aforesaid | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Cambridge Healthcare Research Limited
- Other trademarks owned by Cambridge Healthcare Research Limited
- Other trademarks owned by Cambridge Healthcare Research Limited
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named SOLICI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 2, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 7, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Nov 29, 2025 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Mar 1, 2025 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 1, 2025 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 12, 2025 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 12, 2025 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 10, 2025 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 8, 2025 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Nov 21, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 20, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 20, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 4, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 4, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 15, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 8, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 29, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 29, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 29, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 29, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 17, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 16, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 29, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 28, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 15, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 27, 2023 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Sep 27, 2023 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 27, 2023 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 27, 2023 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Sep 27, 2023 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Sep 12, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 8, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 7, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |